

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT NHI:</b> .....	<b>REFERRER</b> Reg No: .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	Address: .....	.....
.....	.....	.....
Fax Number: .....	.....	Fax Number: .....

**Antiretrovirals**

**Initial application — Confirmed HIV**

Applications only from a named specialist. Approvals valid without further renewal unless notified.

**Prerequisites**(tick box where appropriate)

The patient has confirmed HIV infection

Note: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

**Renewal — Confirmed HIV**

Current approval Number (if known):.....

Applications only from a named specialist. Approvals valid without further renewal unless notified.

**Prerequisites**(tick box where appropriate)

The treatment remains appropriate and the patient is benefiting from treatment

**Initial application — Prevention of maternal transmission**

Applications only from a named specialist. Approvals valid for 1 year.

**Prerequisites**(tick boxes where appropriate)

<input type="checkbox"/> Prevention of maternal foetal transmission <b>or</b> <input type="checkbox"/> Treatment of the newborn for up to eight weeks
---

Note: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals.

Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

**I confirm the above details are correct and that in signing this form I understand I may be audited.**

Signed: ..... Date: .....

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)

**APPLICANT** (stamp or sticker acceptable)      **PATIENT NHI:** .....      **REFERRER** Reg No: .....

Reg No: .....      First Names: .....      First Names: .....

Name: .....      Surname: .....      Surname: .....

Address: .....      DOB: .....      Address: .....

.....      Address: .....      .....

.....      .....

Fax Number: .....      Fax Number: .....

**Antiretrovirals - continued**

**Initial application — post-exposure prophylaxis following exposure to HIV**

Applications from any relevant practitioner. Approvals valid for 4 weeks.

**Prerequisites**(tick boxes where appropriate)

Treatment course to be initiated within 72 hours post exposure

**and**

Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml

**or**

Patient has shared intravenous injecting equipment with a known HIV positive person

**or**

Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required

**or**

Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown

Note: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals. Refer to local health pathways or the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine clinical guidelines for PEP (<https://www.ashm.org.au>)

**Renewal — second or subsequent post-exposure prophylaxis**

Current approval Number (if known):.....

Applications from any relevant practitioner. Approvals valid for 4 weeks.

**Prerequisites**(tick boxes where appropriate)

Treatment course to be initiated within 72 hours post exposure

**and**

Patient has had condomless anal intercourse or receptive vaginal intercourse with a known HIV positive person with an unknown or detectable viral load greater than 200 copies per ml

**or**

Patient has shared intravenous injecting equipment with a known HIV positive person

**or**

Patient has had non-consensual intercourse and the clinician considers that the risk assessment indicates prophylaxis is required

**or**

Patient has had condomless anal intercourse with a person from a high HIV prevalence country or risk group whose HIV status is unknown

**Initial application — Percutaneous exposure**

Applications only from a named specialist. Approvals valid for 6 weeks.

**Prerequisites**(tick box where appropriate)

The patient has percutaneous exposure to blood known to be HIV positive

Note: Tenofovir disoproxil prescribed under endorsement for HIV is included in the count of up to 4 subsidised antiretrovirals. Subsidies apply for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

**I confirm the above details are correct and that in signing this form I understand I may be audited.**

Signed: ..... Date: .....

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)

<b>APPLICANT</b> (stamp or sticker acceptable)	<b>PATIENT NHI:</b> .....	<b>REFERRER Reg No:</b> .....
Reg No: .....	First Names: .....	First Names: .....
Name: .....	Surname: .....	Surname: .....
Address: .....	DOB: .....	Address: .....
.....	Address: .....	.....
.....	.....	.....
Fax Number: .....	.....	Fax Number: .....

**Antiretrovirals** - *continued*

**Renewal — Second or subsequent percutaneous exposure**

Current approval Number (if known):.....

Applications only from a named specialist. Approvals valid for 6 weeks.

**Prerequisites**(tick box where appropriate)

The patient has percutaneous exposure to blood known to be HIV positive

I confirm the above details are correct and that in signing this form I understand I may be audited.

Signed: ..... Date: .....

Post application to Health New Zealand, Private Bag 3015, Wanganui – email: [customerservice@health.govt.nz](mailto:customerservice@health.govt.nz)